Mesothelioma and dendritic cell therapy: encouraging results from Phase I trials of dendritic cell therapy in mesothelioma - asbestos cancer, released at ASCO 2010. Article updated June 9, 2010

June 22, 2011: Please read the recently added information about Dr. Robert Gorter and Medical Center in Cologne this information: My experience with dr.Robert Gorter and the Medical Center Cologne. A warning

And click here for addresses of clinics in Germany, where dendritic cell therapy is given .

June 9, 2010: ASCO 2010 and Citation: J Clin Oncol 28, 2010 (suppl, abstr e13063)

A new phase I study again shows that dendritic cell therapy is a possible continuation treatment for mesothelioma lung cancer patients with the first treatment has failed. And the belanfgirjk therpaie gave no serious side effects is a small study: 14 patients with mesothelioma in the lung Grade IV participated. The result was that in three cases there was stable disease and one a partial remission. Unbeatable with other studies listed below, including a mouse study and a Phase I study from the Erasmus Rotterdam and Radboud. Here is the abstract of the new phase I study presented at ASCO 2010:

Immunotherapy with dendritic cells as a second-line therapy in advanced pleural mesothelioma

Citation: J Clin Oncol 28, 2010 (suppl, abstr e13063)

Author (s): J. Nesselhut, D. Marx, RY Chang, D. Lorenzen, N. Cillien, W. Goebel, F. Fändrich, T. Nesselhut, Institut fuer Tumor Therapy, Duderstadt, Germany, Meridian Medical Group, New York, NY; Clinic for Applied Cellular Medicine, University Hospital SH, Kiel, Germany

 

Background: Malignant pleural mesothelioma (MPM) is an aggressive disease with an unfavorable Prognosis. The current front-line treatment for cisplatin in combination was nonoperable internships with pemetrexed chemotherapy. The reported median overall survival times are less than 15 months. After failure of first-line therapy there is currently no proven effective therapy, whereas potential side effects from treatments Further May Impair Quality of Life. In Those cases, we report That immunotherapy with monocyte-derived dendritic cells (MoDC) can be effective without significant impact on life quality.

Methods: After isolating monocytes from peripheral blood or n = 14 patients with stage 4 MPM who failed first-line chemotherapy, MoDC were generated Using standard protocols. The MoDC were primed on day 5 with tumor lysate and co-cultured with toll-like receptor ligands to induce a TH1-Polarisation of the MoDC. In one case, an allogeneic cell line lysed by the oncolytic Newcastle disease virus (NDV) was overused. This patient received an injection NDV one day before the DC Administration. In general, the MoDC were harvested on day 7 and Administered to the patient, intradermally.

Results: We Were Able to induce a clinical response in 29% of the patients (n = 3 Stabilization, a partial remission). The median survival after onset of DC therapy was 7 months (1-26 months) and 24 months (7-33 months) after primary diagnosis. The therapy was well tolerated without having any major side effects. Interestingly, the patient showing a partial remission received the NDV-modified vaccine. IFN-gamma ELISPOT analysis from Patients who received injections NDV and NDV-modified MoDC That show MoDC primed with NDV lysed tumor cells can induce a specific CD4 and CD8 T-cell response against the tumor cells lysed NDV whereas healthy donors show no specific T-cell response.  

Conclusions: Immunotherapy with dendritic cells May ProLong the overall survival or patient with MPM after failure of first-line therapy without significant impact on the quality of life. For the first time, we demonstrated NDV That is bootable to infect MPM cells, leading to cell lysis or thesis.

April 16 Nijmegen010 2: Source: Am J Respir Crit Care Med. February 18 2010.

Following studies with mice. see sidebar in the left column about the study, says the Erasmus Medical Centre Rotterdam, a first phase I study in 10 patients with an incurable form of lung cancer because asbestos cancer - mesothelioma promising results. After four years a patient is still alive told investigator Dr. Joachim Aerts with the newspaper.

None of the 10 participating patients had side effects except fever, which always evokes dendritic cell therapy. See also the videos of patients who were treated with dendritic cell therapy in the Medical Center Cologne . Results of progress of the cancer itself is not disclosed by researchers at the Erasmus Medical Center Rotterdam. Therefore it is too early investigator said Dr.. Joachem Aerts.

Consolidative Dendritic Cell-Based Immunotherapy Malignant Mesothelioma Elicit Cytotoxicity Against

Joost P 1 Hegman, George D. Veltman 1, Margaret E Lambers 1, I. Jolanda M. de Vries 2, Carl G. Figdor 2, Rudi W Hendriks 1, Henk C. 1 Hoogsteden, Bart N. Lambrecht 3, and Joachim G. Aerts 4 *

1 Pulmonary Medicine, Erasmus MC, Rotterdam, Netherlands, 2 Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Nijmegen, Netherlands, 3 Respiratory Medicine, Ghent University, Ghent, Belgium, Pulmonary Medicine, Erasmus MC, Rotterdam, Netherlands, 4 Pulmonary Medicine , Erasmus MC, Rotterdam, Netherlands, Pulmonary Medicine, Amphia Hospital, Breda, Netherlands

Rationale: We have demonstrated EARLIER That dendritic cell based immunotherapy induced protective antitumor immunity with prolonged survival in mice. However, the clinical relevance is still questioned. We designed a clinical trial Using chemotherapy followed by antigen-pulsed dendritic cell vaccination in Mesothelioma Patients

Objectives: The aim of this study was to Assess the Safety and immuno-logical response induced by the administration or tumor lysate-pulsed dendritic cells in mesothelioma patient.

Methods: Ten Patients with malignant pleural mesothelioma received three vaccination of clinical-grade autologous dendritic cells intradermally and intravenously at two-week intervals after chemotherapy. Each vaccine was composed of mature dendritic cells pulsed 50x10 6 with autologous tumor lysate and keyhole limpet hemocyanin (KLH) as surrogate marker. Delayed-type hypersensitivity activity to tumor antigens and KLH was reassessed, Both in vivo and in vitro. Peripheral blood mononuclear cells During the treatment Were Analyzed for Immunological responses. Main Results: Administration or dendritic cells pulsed with autologous tumor lysate in mesothelioma Patients with moderate fever was safe as the only side effect. There were no grade 3 or 4 toxicities associated with the vaccines or any evidence of autoimmunity. Local Accumulation of Infiltrating T cells were found at the site of vaccination. The vaccination induced distinct immuno-logical responses to KLH, Both in vitro and in vivo. Importantly, after three vaccination, cytotoxic activity against autologous tumor cells were detected in a subgroup or patients.

Conclusions: This study demonstrated autologous That tumor lysate-pulsed dendritic cell based therapy is Feasible, well-tolerated, and capable of inducing immune response logical to tumor cells of mesothelioma patient. www.clinicaltrials.gov NCT00280982